Float Short %

2.92

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.01

EPS Last/This Y

-1.97

EPS This/Next Y

0.16

Price

10.8

Target Price

10.88

Analyst Recom

Performance Q

288.26

Relative Volume

1.16

Beta

0.99

Ticker: LPCN

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	LPCN	5.22	N/A	N/A	0
2025-12-29	LPCN	6.32	N/A	N/A	0
2025-12-30	LPCN	6.56	N/A	N/A	0
2025-12-31	LPCN	7.91	N/A	N/A	0
2026-01-02	LPCN	7.99	N/A	N/A	0
2026-01-05	LPCN	7.31	N/A	N/A	0
2026-01-06	LPCN	7.62	N/A	N/A	0
2026-01-07	LPCN	7.53	N/A	N/A	0
2026-01-08	LPCN	7.56	N/A	N/A	0
2026-01-09	LPCN	8.05	N/A	N/A	0
2026-01-12	LPCN	9.12	N/A	N/A	0
2026-01-13	LPCN	10.5	N/A	N/A	0
2026-01-14	LPCN	10.99	N/A	N/A	0
2026-01-15	LPCN	11.26	N/A	N/A	0
2026-01-16	LPCN	11.21	N/A	N/A	0
2026-01-20	LPCN	9.93	N/A	N/A	0
2026-01-21	LPCN	9.73	N/A	N/A	0
2026-01-22	LPCN	10.44	N/A	N/A	0
2026-01-23	LPCN	10.68	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	LPCN	5.20	-	-	-1.97
2025-12-29	LPCN	6.32	-	-	-1.97
2025-12-30	LPCN	6.53	-	-	-1.97
2025-12-31	LPCN	8.18	-	-	-1.97
2026-01-02	LPCN	7.95	-	-	-1.97
2026-01-05	LPCN	7.38	-	-	-1.97
2026-01-06	LPCN	7.57	-	-	-1.97
2026-01-07	LPCN	7.53	-	-	-1.97
2026-01-08	LPCN	7.44	-	-	-1.97
2026-01-09	LPCN	8.04	-	-	-1.97
2026-01-12	LPCN	9.02	-	-	-1.97
2026-01-13	LPCN	10.52	-	-	-1.97
2026-01-14	LPCN	10.92	-	-	-1.97
2026-01-15	LPCN	11.19	-	-	-1.97
2026-01-16	LPCN	11.21	-	-	-1.97
2026-01-20	LPCN	9.95	-	-	-1.97
2026-01-21	LPCN	9.74	-	-	-1.97
2026-01-22	LPCN	10.62	-	-	-1.97
2026-01-23	LPCN	10.80	-	-	-1.97
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	LPCN	0.00	0.02	2.06
2025-12-29	LPCN	0.00	0.02	2.06
2025-12-30	LPCN	0.00	0.02	2.06
2025-12-31	LPCN	0.00	0.02	2.06
2026-01-02	LPCN	0.00	0.02	2.06
2026-01-05	LPCN	0.00	0.02	2.06
2026-01-06	LPCN	0.00	0.02	2.06
2026-01-07	LPCN	0.00	0.02	2.06
2026-01-08	LPCN	0.00	0.02	2.06
2026-01-09	LPCN	0.00	0.02	2.06
2026-01-12	LPCN	0.00	0.02	2.06
2026-01-13	LPCN	0.00	0.02	2.92
2026-01-14	LPCN	0.00	0.02	2.92
2026-01-15	LPCN	0.00	0.02	2.92
2026-01-16	LPCN	0.00	0.02	2.92
2026-01-20	LPCN	0.00	0.02	2.92
2026-01-21	LPCN	0.00	0.02	2.92
2026-01-22	LPCN	0.00	0.02	2.92
2026-01-23	LPCN	0.00	0.02	2.92
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.59

Avg. EPS Est. Current Quarter

-0.61

Avg. EPS Est. Next Quarter

-0.6

Insider Transactions

Institutional Transactions

0.02

Beta

0.99

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

73.1

Max Drawdown 5-Year %

-93.8

Target Price

10.88

P/E

Forward P/E

PEG

P/S

14.02

P/B

4.18

P/Free Cash Flow

EPS

-1.02

Average EPS Est. Cur. Y

-1.97

EPS Next Y. (Est.)

-1.81

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-126.66

Relative Volume

1.16

Return on Equity vs Sector %

-66

Return on Equity vs Industry %

-50

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.11

EBIT Estimation

Lipocine Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 16

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

stock quote shares LPCN – Lipocine Inc Stock Price stock today

news today LPCN – Lipocine Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch LPCN – Lipocine Inc yahoo finance google finance

stock history LPCN – Lipocine Inc invest stock market

stock prices LPCN premarket after hours

ticker LPCN fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: LPCN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y